Back to top

AcelRx Pharmaceuticals (ACRX) in Focus: Stock Moves 19.6% Higher
October 03, 2017

Read MoreHide Full Article

AcelRx Pharmaceuticals, Inc. (ACRX - Free Report) was a big mover last session, as the company saw its shares rise nearly 20% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent trend for the company—as the stock is now up 35.4% in the past one-month time frame.

The stock price might have appreciated in anticipation of an FDA approval for AcelRx's pain medication Dsuvia.

The company has seen no estimate revisions over the past one month, and the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

AcelRx Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP  is 0.00%.

AcelRx Pharmaceuticals, Inc. Price and Consensus

A better-ranked stock in the Medical - Drugsindustry is MEI Pharma, Inc.(MEIP - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ACRX going up? Or down? Predict to see what others think: Up or Down

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


MEI Pharma, Inc. (MEIP) - free report >>

AcelRx Pharmaceuticals, Inc. (ACRX) - free report >>


More from Zacks Tale of the Tape

You May Like